Intranasal Administration of Apelin-13 Ameliorates Cognitive Deficit in Streptozotocin-Induced Alzheimer’s Disease Model via Enhancement of Nrf2-HO1 Pathways
Open Access
- 11 May 2024
- journal article
- research article
- Published by MDPI AG in Brain Sciences
- Vol. 14 (5) , 488
Abstract
Background: The discovery of novel diagnostic methods and therapies for Alzheimer’s disease (AD) faces significant challenges. Previous research has shed light on the neuroprotective properties of Apelin-13 in neurodegenerative disorders. However, elucidating the mechanism underlying its efficacy in combating AD-related nerve injury is imperative. In this study, we aimed to investigate Apelin-13’s mechanism of action in an in vivo model of AD induced by streptozocin (STZ). Methods: We utilized an STZ-induced nerve injury model of AD in mice to investigate the effects of Apelin-13 administration. Apelin-13 was administered intranasally, and cognitive impairment was assessed using standardized behavioral tests, primarily, behavioral assessment, histological analysis, and biochemical assays, in order to evaluate synaptic plasticity and oxidative stress signaling pathways. Results: Our findings indicate that intranasal administration of Apelin-13 ameliorated cognitive impairment in the STZ-induced AD model. Furthermore, we observed that this effect was potentially mediated by the enhancement of synaptic plasticity and the attenuation of oxidative stress signaling pathways. Conclusions: The results of this study suggest that intranasal administration of Apelin-13 holds promise as a therapeutic strategy for preventing neurodegenerative diseases such as AD. By improving synaptic plasticity and mitigating oxidative stress, Apelin-13 may offer a novel approach to neuroprotection in AD and related conditions.Keywords
All Related Versions
This publication has 41 references indexed in Scilit:
- Neuroprotective Roles of Apelin-13 in Neurological DiseasesNeurochemical Research, 2023
- Apelin-13 Improves Cognitive Impairment and Repairs Hippocampal Neuronal Damage by Activating PGC-1α/PPARγ SignalingNeurochemical Research, 2022
- Apelin/APJ system: an emerging therapeutic target for neurological diseasesMolecular Biology Reports, 2022
- Research Progress on Mechanism of Neuroprotective Roles of Apelin-13 in Prevention and Treatment of Alzheimer’s DiseaseNeurochemical Research, 2021
- Apelin/APJ system: A novel promising target for neurodegenerative diseasesJournal of Cellular Physiology, 2019
- Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical EvidenceCNS Drugs, 2013
- Intranasal insulin as a therapeutic option in the treatment of cognitive impairmentsExperimental Gerontology, 2011
- Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in miceEuropean Journal of Pharmacology, 2008
- Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemiareperfusion injuryBasic Research in Cardiology, 2007
- Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ ReceptorBiochemical and Biophysical Research Communications, 1998